Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature
Sandra Zingg, Giuseppe Nicoletti, Sabine Kuster, Milena Junker, Andreas F. Widmer, Adrian Egli, Vladimira Hinić, Parham Sendi, Manuel Battegay, Veronika Bättig, Nina Khanna, Sarah Tschudin‐Sutter
Abstract
Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract infections. We present a series of 3 patients successfully treated with cefiderocol for complicated health care-associated infections and review published case reports.
Topics & Concepts
CephalosporinMedicineSiderophoreCarbapenemIntensive care medicineUrinary systemGramMicrobiologyAntibioticsBacteriaBiologyInternal medicineGeneticsAntibiotic Resistance in BacteriaUrinary Tract Infections ManagementAntibiotics Pharmacokinetics and Efficacy